与SGLT2i与GLP-1RA相关的Phimosis风险:一项丹麦队列研究
Christine Ljungberg1, Mette Nørgaard1, Christina Vandenbroucke-Grauls1,2
1Department of Clinical Epidemiology, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Diabetes care
|July 30, 2025
概括
与葡萄糖类-1受体激活剂 (GLP-1RA) 相比,-葡萄糖共运输体2抑制剂 (SGLT2i) 在患有2型糖尿病的男性中几乎增加了双倍的发病风险. 这种高风险持续超过8年的随访.
科学领域:
- 内分泌学 在内分泌学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病的管理通常涉及具有不同副作用的药物.
- 已知-葡萄糖共运输体2抑制剂 (SGLT2i) 诱导葡萄糖尿,可能改变当地的微环境.
- 影响前皮的一种疾病 - - 菲莫西斯 (Phimosis) 曾经与SGLT2i使用有关.
研究的目的:
- 调查启动SGLT2抑制剂与类似葡萄糖-1受体激动剂之间的关联,以及2型糖尿病成年男性发病的风险.
- 量化这两种常见的糖尿病药物类别之间的相对发病风险.
主要方法:
- 使用丹麦医疗数据库进行了基于人口的,主动比较的新用户队列研究.
- 包括2016年至2021年期间启动SGLT2i或GLP-1RA的成年男性甲福明使用者.
- 使用治疗逆概率加权来平衡混因素,并计算出治疗意向风险和风险比率.
主要成果:
- 该研究包括32486名SGLT2i发起者和14793名GLP-1RA发起者,随访时间中位数为4年 (长达8年).
- 对于SGLT2i使用者来说,一年内发病的风险为0.9%,对于GLP-1RA使用者来说为0.5%,风险比为1.88 (95% CI,1.43至2.47).
- 在8年内,SGLT2i使用者的累计发病风险达到4.8%,GLP-1RA使用者的累计发病风险达到3.6% (风险比,1.36;95% CI,1.14至1.61).
结论:
- 与GLP-1RA使用相比,使用-葡萄糖共运输体2抑制剂与患有2型糖尿病的男性中发炎风险显著增加有关.
- 与SGLT2i启动相关的瘤发作的风险在第一年内几乎增加了两倍,并在8年的随访期间保持高水平.
- 这些发现突出了与SGLT2i治疗相关的潜在泌尿器官风险,需要在临床实践中考虑.
相关概念视频
Glucose Transporters
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetic Retinopathy
DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...


